Background
It has been proposed that magnetic resonance imaging (MRI) be used to guide breast cancer surgery by differentiating residual tumor from pathologic complete response (pCR) after neoadjuvant chemotherapy. This metaanalysis examines MRI accuracy in detecting residual tumor, investigates variables potentially affecting MRI performance, and compares MRI with other tests.
Methods
A systematic literature search was undertaken. Hierarchical summary receiver operating characteristic (HSROC) models were used to estimate (relative) diagnostic odds ratios ([R]DORs). Summary sensitivity (correct identification of residual tumor), specificity (correct identification of pCR), and areas under the SROC curves (AUCs) were derived. All statistical tests were two-sided.
Results
Forty-four studies (2050 patients) were included. The overall AUC of MRI was 0.88. Accuracy was lower for "standard" pCR definitions (referent category) than "less clearly described" (RDOR = 2.41, 95% confidence interval [CI] = 1.11 to 5.23) or "near-pCR" definitions (RDOR = 2.60, 95% CI = 0.73 to 9.24; P = .03.) Corresponding AUCs were 0.83, 0.90, and 0.91. Specificity was higher when negative MRI was defined as contrast enhancement less than or equal to normal tissue (0.83, 95% CI = 0.64 to 0.93) vs no enhancement (0.54, 95% CI = 0.39 to 0.69; P = .02), with comparable sensitivity (0.83, 95% CI = 0.69 to 0.91; vs 0.87, 95% CI = 0.80 to 0.92; P = .45). MRI had higher accuracy than mammography (P = .02); there was only weak evidence that MRI had higher accuracy than clinical examination (P = .10). No difference in MRI and ultrasound accuracy was found (P = .15).
Conclusions
MRI accurately detects residual tumor after neoadjuvant chemotherapy. Accuracy was lower when pCR was more rigorously defined, and specificity was lower when test negativity thresholds were more stringent; these definitions require standardization. MRI is more accurate than mammography; however, studies comparing MRI and ultrasound are required. J Natl Cancer Inst;2013;105: [321] [322] [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] Neoadjuvant chemotherapy (NAC) has a well-established role in the management of breast cancer (1) (2) (3) (4) . For women with operable disease at presentation, the primary aim of NAC is the achievement of pathologic complete response (pCR) prior to surgery (5, 6) , which has been shown to confer improvements in long-term disease-free and overall survival relative to cases in which residual invasive tumor remains after NAC (7, 8) . Accurate ascertainment of whether pCR has been achieved or, conversely, accurate detection of the presence of residual tumor is needed to inform surgical planning (9) . Currently, assessment of the presence or absence of residual tumor after NAC informs the extent of subsequent surgery; however, the avoidance of surgery remains a future goal for patients in whom an absence of residual tumor can be accurately detected (10) .
Various breast imaging modalities have been used to detect whether residual malignancy is present or absent after NAC, of which magnetic resonance imaging (MRI) has been increasingly used and recommended in recent years (9, 11) . In this systematic review, we examine the evidence on the ability of MRI to identify whether residual malignancy is present or whether pCR has been achieved at completion of NAC, report estimates of MRI accuracy and comparative accuracy, and investigate variables potentially affecting MRI accuracy in the NAC setting.
Methods

Identification of Studies
A systematic search of the biomedical literature up to February 2011 was undertaken to identify studies assessing the accuracy of MRI after NAC in differentiating the presence of residual tumor from the absence of disease (ie, pCR). MEDLINE and EMBASE
Data Extraction
Data that was related to test accuracy, study design, patient characteristics, tumors, treatment, technical details of MRI, comparator tests, and the reference standard were extracted independently by two authors (M. L. Marinovich, and either S. Ciatto, M.E. Brennan, or F. Sardanelli). Study-level definitions of pathologic response and MRI thresholds for the absence of residual tumor were categorized according to the criteria in Supplementary Appendix C (available online). Quality appraisal was undertaken using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist (modified for application to studies of residual tumor detection in this setting) (13, 14) . Disagreements were resolved by discussion and consensus, with arbitration by a third author (N. Houssami) when required.
Statistical Analysis
Descriptive analyses were conducted using coupled forest plots and scatter plots of study-specific estimates of sensitivity and specificity. Because studies varied in the criterion used to define a positive test result, the Rutter and Gatsonis hierarchical summary receiver operating characteristic (HSROC) model (15) was used to model MRI accuracy in terms of the diagnostic odds ratio (DOR): [sensitivity/(1−sensitivity)]/[(1−specificity)/specificity]. The DOR is the ratio of the odds of MRI being positive when residual tumor is truly present relative to the odds of MRI being positive when pCR has been achieved. A DOR of 1 means that the test does not discriminate between patients with and without residual tumor; higher values indicate better test performance (16) . The HSROC model takes into account uncertainty in estimates of sensitivity and specificity within studies, as well as additional unexplained variation (heterogeneity) between studies, by the inclusion of random study effects for test accuracy and threshold (a function of the underlying test positivity rate). A shape parameter, fitted in the model as a fixed effect, allows for asymmetry in the SROC curve (ie, variation in accuracy by test threshold). For a symmetrical SROC curve, the estimated log e (DOR) is constant across thresholds. Supplementary Appendix D (available online) shows a detailed specification of the model. HSROC models were fitted using PROC NLMIXED in SAS version 9.2 (SAS Institute, Cary, NC) (17) . The distribution of the random effects for accuracy and threshold was checked for each model to ensure that normality assumptions were met. For models in which the variation in accuracy between studies was observed to be negligible, test accuracy was modeled as a fixed effect. Further detail of the model-fitting strategy is described by Macaskill (18) .
Covariables were added to the HSROC model to assess whether the shape or position (accuracy) of the SROC curve(s) was associated with differences in patient, test, treatment, and study characteristics. Covariables were age (median of <50 years vs >50 years); histology (proportion that was invasive ductal carcinoma); stage (proportion that was stage I/II); human epidermal growth factor receptor 2 and estrogen receptor status (proportion that was receptor positive); chemotherapy type (anthracycline-based, anthracycline/taxanebased, anthracyclines/taxanes alone or combined, other); surgery type (proportion that was mastectomy); time from MRI to surgery (mean); midpoint of study enrollment period; definition of pCR (see Supplementary Appendix C, available online); prevalence of pCR; comparative vs noncomparative study design; prospective vs retrospective design; and consecutive vs nonconsecutive patient enrollment. Each covariable was modeled separately, and their contributions to the model were assessed by the likelihood ratio test (19) . Where subgroups of studies used equivalent MRI contrast enhancement thresholds (ie, no contrast enhancement vs enhancement less than or equal to normal breast tissue) to define a negative result for residual tumor, summary estimates of sensitivity and specificity were derived for these thresholds. Ninetyfive percent confidence intervals (CIs) for the expected sensitivity and specificity and the t statistics and corresponding P values for differences between MRI thresholds were derived using the ESTIMATE command in PROC NLMIXED (18) .
The HSROC model was also used to compare the test performance of MRI relative to ultrasound, clinical examination, and mammography for subgroups of studies in which MRI and at least one comparator test were evaluated in the same patients (or in patient groups that substantially overlapped). Test type was included as a covariable, with separate models used for each comparison.
Where there was no evidence of asymmetry in the estimated SROC curves (assessed by the likelihood ratio test), the shape parameter was set to zero, and the relative DOR (RDOR) was used to compare accuracy for levels of the covariable. Ninety-five percent confidence intervals for RDORs were derived from the asymptotic standard error of the estimate reported by PROC NLMIXED and assuming a t distribution, as described previously (18) . The area under the curve (AUC) for each fitted SROC was computed by the method described by Walter (20) to provide a global measure of accuracy or using numerical integration when curves were asymmetric. The fitted curves were displayed graphically, superimposed on a scatter-plot in ROC space of study-specific estimates of (sensitivity, 1-specificity) pairs. Plotted curves were restricted to the range of data points.
Differences in QUADAS items between studies were tested using χ 2 or Fisher exact tests, as appropriate. All tests of statistical significance were two-sided; the level chosen for statistical significance was .05.
Results
Study Characteristics
A total of 2107 citations were identified. Forty-four studies were eligible for inclusion in our meta-analysis, reporting data on 2949 patients (n = 2967 cancers) undergoing MRI and/or comparator tests; MRI data were reported for 2050 patients (n = 2068 cancers). Studies enrolled patients between 1990 and 2008 (median midpoint of recruitment = year 2001) and included a median of 36 patients in the analysis of MRI accuracy (range = 14-208). Characteristics of included studies are summarized in Table 1 and Supplementary Appendices C (pCR definitions and MRI thresholds) and E (MRI technical characteristics) (available online).
Patients enrolled in included studies had predominantly stage II and III cancer, and the majority had invasive ductal carcinoma (see Table 1 ). NAC was primarily anthracycline-taxane based, either sequential or in combination. Trastuzumab was used in 11 studies (range of patients within studies = 1.5%-62.5%). Radiotherapy was given before surgery in two studies (54, 64) . For studies that specified the type of surgery undertaken, a majority of patients underwent breast conservation. Study quality appraisal is summarized in Supplementary Appendix F (available online).
MRI Details
The majority of studies used dynamic contrast-enhanced MRI (86.4%) with a 1.5-T magnet (77.3%). Dedicated bilateral breast coils were used in all studies in which the coil type was reported. All studies that provided detail on contrast employed gadolinium-based materials, most commonly gadopentetate dimeglumine (50.0%), typically at the standard dosage of 0.1 mmol/kg body weight (61.4%) (see Supplementary Appendix E, available online). Ten studies (22.7%) (27, (29) (30) (31) (32) 37, 38, 42, 46, 50) considered MRI to be negative (absence of residual tumor) when there was an absence of contrast enhancement; a further six studies (13.6%) (23, 24, 26, 40, 49, 57) defined MRI negativity as contrast enhancement less than or equal to normal breast tissue. The remaining studies either did not report MRI negativity in terms of the degree of contrast enhancement (n = 20, 45.4%) (21, 22, 25, 33, 34, 36, 39, 41, (43) (44) (45) 48, 52, 54, 56, 58, 59, (61) (62) (63) or did not specify a threshold (n = 8, 18.2%) (28, 35, 47, 51, 53, 55, 64 ) (see Supplementary Appendix C, available online).
Reference Standard
Pathology from surgical excision was the reference standard for all patients in all but two studies; test results were verified by localization biopsy in a small number (6.2%) of patients in one study (36) and by follow-up (41.2%) in another (64) .
Definitions of reference standard positivity (presence of residual tumor) and negativity (pCR) varied across studies (see Supplementary Appendix C, available online). Twenty studies (21, (23) (24) (25) 27, (30) (31) (32) (33) 36, 37, 41, 43, 44, 48, 52, 56, 57, 59 ,62) (45.5%) defined pCR as the absence of invasive cancer on pathological examination, with or without the presence of ductal carcinoma in situ (DCIS; ie, residual DCIS was considered negative). Nine of these studies (27, 30, 32, 36, 37, 41, 44, 56, 57) provided data that allowed DCIS to be classified as either positive or negative for residual disease; primary analyses classified DCIS as negative on the reference standard, consistent with the Miller-Payne grading system (65) , and the effect of classifying residual DCIS as positive in these studies was explored in sensitivity analyses. In four additional studies (9.1%) (34, 45, 50, 53) , pCR was defined as the absence of any residual invasive cancer or DCIS (ie, residual DCIS was considered positive). In 12 studies (27.3%) (26, (38) (39) (40) 46, 47, 49, 51, 58, 60, 61, 63) , nonspecific definitions that did not describe whether residual DCIS was considered positive or negative (eg, pCR was defined simply as the absence of residual disease/malignancy or the measurement of residua being zero) were employed. Four studies (9.1%) (28, 42, 54, 55) allowed reference standard negativity to include small clusters of microscopic invasive cells or similar definitions of minimal residual disease ("near-pCR"). A further four studies (9.1%) (22, 29, 35, 64) did not define reference standard positivity and negativity.
pCR Rates
Study-specific pCR rates ranged between 2.6% and 54.9%, with a median of 16.0%. The rates are presented in Supplementary Appendix G (available online), stratified by response definition.
Accuracy of MRI
Study-specific estimates of MRI sensitivity and specificity are presented in Figure 1 . Median sensitivity across studies was 0.92 (interquartile range [IQR] = 0.85-0.97), and median specificity was 0.60 (IQR = 0.39-0.96). Table 2 reports the overall and covariablespecific modeled estimates of MRI accuracy (derived from separate models for each covariable); in all but one of these models (midpoint of patient enrollment = year 2000 or earlier vs year 2001 or later), the shape parameter was not statistically significant (ie, SROC curves were symmetrical). Overall, the AUC for MRI based on all 44 studies was 0.88; the SROC curve for all studies is shown in Figure 2 .
MRI accuracy (DOR) differed according to the applied studylevel definition of pCR (P = .03). Figure 3 displays SROC curves stratified by pCR definition. Accuracy was lowest in studies that permitted residual DCIS in the definition of pCR; relative to this referent group, accuracy was higher in studies that excluded residual DCIS from the definition of pCR (RDOR = 1.31, 95% CI = 0.33 to 5.20), applied a nonspecific definition of reference standard positivity/negativity (RDOR = 2.41, 95% CI = 1.11 to 5.23), or used a near-pCR definition (RDOR = 2.60, 95% CI = 0.73 to 9.24). Relatively few studies excluded DCIS from the pCR definition (n = 4) or used a near-pCR outcome (n = 4); hence confidence * BCS = breast conserving surgery; DCIS = ductal carcinoma in situ; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; IQR = interquartile range; MRI = magnetic resonance imaging; NAC = neoadjuvant chemotherapy; NR = not reported; pCR = pathologic complete response; PR = progesterone receptor; Sx = surgery. † Values based on the number of cancers. ‡ Used in 11 studies, but figures based on 10 studies for which the proportion of patients who received trastuzumab was reported. 7  14  11  16  130  46  45  43  22  56  12  39  30  24  84  18  37  37  10  10  41  18  21  25  160  28  28  30  62  34  36  39  40  53  15  44  24  10  11  18  13  10   FP   0  3  1  2  5  2  14  0  0  3  3  6  3  2  2  1  11  2  0  0  2  0  3  1  2  2  18  0  0  3  9  7  1  11  3  8  3  5  3  2 However, different SROC curve shapes were observed for earlier and later studies (P = .01) (see Supplementary Appendix H, available online); it is therefore not possible to report single DORs (or a RDOR) as summary measures of accuracy. Earlier studies reported consistently high sensitivity across the range of specificity values, whereas a trade-off between sensitivity and specificity at different thresholds was evident in later studies. Studies with a midpoint of patient enrollment of year 2000 or earlier reported higher overall accuracy than those with a midpoint of year 2001 or later (AUC = 0.92 vs 0.83). Comparison of QUADAS items between earlier vs later studies suggested no major differences in study quality between levels of this covariable (P > .05 for all QUADAS items). No statistical evidence was found for associations between MRI accuracy and other variables related to study design, patient characteristics, and treatment characteristics ( Table 2) .
Sensitivity analyses, in which modelling was repeated with changed pCR definitions in nine studies (see "Reference Standard"), resulted in similar parameter estimates to those in the primary analysis. Sensitivity analyses were also undertaken to exclude one study (23) with a patient cohort that overlapped with a second study (24) ; additional analyses excluded two studies that did not use a reference standard of pathologic examination in all patients (36, 64) . Exclusion of these studies did not substantially affect parameter estimates.
Threshold-Specific Sensitivity and Specificity of MRI
Ten studies used a complete absence of MRI enhancement to identify pCR (threshold 1), and six studies used contrast enhancement equal to or less than normal breast tissue to define a negative MRI result (threshold 2). The summary estimate of specificity was higher for threshold 2 (0.83, 95% CI = 0.64 to 0.93) than for threshold 1 (0.54, 95% CI = 0.39 to 0.69; P = .02), with comparable pooled sensitivity (0.83, 95% CI = 0.69 to 0.91; vs 0.87, 95% CI = 0.80 to 0.92; P = .45). Summary estimates are displayed in Supplementary Appendix I (available online). (34, 36, 43, 50, 54, 55, 64) ]. There was evidence that mammography had lower accuracy than MRI (RDOR = 0.27, 95% CI = 0.07 to 1.02; P = .02) (AUC = 0.89 vs 0.95; SROC presented in Figure 4 ). The analysis was repeated after removing one potentially influential study (36) , and the statistically significant difference in accuracy between MRI and mammography remained (RDOR = 0.36, 95% CI = 0.08 to 1.60; P = .04), with comparable AUCs (0.88 vs 0.94).
Comparisons of the Accuracy of MRI and Other Tests
There was only weak evidence that clinical examination had lower accuracy than MRI (RDOR = 0.53, 95% CI = 0.22 to 1.28; P = .10; AUC = 0.83 vs 0.89; SROC presented in Figure 5 ). Accuracy favored MRI in four studies; in the remaining seven studies, MRI was observed to have higher sensitivity but lower specificity than clinical examination. The lower accuracy observed for ultrasound compared with MRI was not statistically significant (RDOR = 0.54, 95% CI = 0.20 to 1.44; P = .15; AUC 0.90 vs 0.93; SROC presented in Figure 6 ). Differences in sensitivity were generally small in all 10 studies comparing the tests; in three of four studies with relatively larger differences in specificity, this difference favored MRI.
Discussion
In the neoadjuvant setting, accurate information on whether residual malignancy is present or whether pCR has been achieved assists in guiding surgical management of breast cancer. We modeled the accuracy of breast MRI, when performed preoperatively after NAC, through evidence synthesis from 44 studies (MRI data for 2068 cancers). Studies generally showed high sensitivity (correct detection of residual tumor), with evidence of heterogeneity in the estimates of specificity (correct identification of pCR) (Figure 1) . Our meta-analysis showed that the capability of MRI for differentiating the presence of residual malignancy from pCR had an overall AUC of 0.88 and that overall accuracy differed according to definition of pCR and study timeframe.
Our meta-analysis adds substantially to earlier work (66) , not only by including a greater number of studies but also by addressing comparative accuracy of MRI and other tests. In addition, we extensively explored study-level covariables, which allowed us to identify new associations and to provide methodologically appropriate estimates of sensitivity and specificity according to MRI positivity thresholds. In this meta-analysis, the median pCR rate was 16.0%, and, although this varied across 44 studies (range = 2.6%-54.9%) and an earlier review based on fewer studies suggested MRI accuracy was associated with rates of pCR (66) , there was no statistically significant association between pCR rate and MRI accuracy in our models. However, the accuracy of MRI differed according to pCR definition (P = .03; see Figure 3 ). Relative to a referent group of studies using a clearly described "standard" definition (no invasive tumor, with or without the presence of residual DCIS) the accuracy of MRI was higher in studies using pCR definitions that were not clearly described (RDOR = 2.41, 95% CI = 1.11 to 5.23). Underlying methodological problems within studies may be associated with a poorly defined outcome definition, contributing to an overestimation of the accuracy of MRI relative to studies that employed clearly described standardized definitions of pCR.
Compared with a standard pCR definition, RDORs for studies that defined pCR as an absence of both invasive tumor and DCIS or as near-pCR were 1.31 (95% CI = 0.33 to 5.20) and 2.60 (95% CI = 0.73 to 9.24), respectively. Wide confidence intervals around these estimates reflect relatively few studies using the latter definitions (n = 4 for each definition); however, an increase in accuracy when residual DCIS is excluded vs included in the pCR definition is consistent with previous studies that reported lower MRI sensitivity in detecting DCIS relative to invasive cancer (67) . Similarly, MRI has been observed to have limitations in detecting scattered, microscopic tumor foci after NAC (11, 68) ; the estimated RDOR for nearpCR relative to a standard pCR definition may reflect fewer false * AUC = area under the receiver operating characteristics curve; BCS = breast conserving surgery; CI = confidence interval; DCIS = ductal carcinoma in situ; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; IDC = invasive ductal carcinoma; MRI = magnetic resonance imaging; pCR = pathologic complete response; RDOR = relative diagnostic odds ratio; -= not applicable. † P value from two-sided likelihood-ratio test. ‡ pCR (absence of residual tumor) was considered to be negative on the reference standard. § Curves are not symmetric and do not have the same shape (see figure in Supplementary Appendix H, available online). negatives and a consequent increase in true negative MRI results when a near-pCR definition is used. Given that near-pCR may plausibly overestimate accuracy relative to standard pCR definitions and given the impact of residual malignancy on prognosis (69) , the use of near-pCR as an outcome in the preoperative, post-NAC setting is not recommended. This analysis highlights the importance of standardizing pCR definitions in the NAC setting (70) .
One of the strengths of our work is the characterization (Table 1 ) and evaluation in analysis (Table 2) of a large number of covariables related to study quality, patient characteristics, tumor characteristics, MRI, and treatment. We found that studies with a midpoint of patient enrollment of year 2000 or earlier reported higher overall AUC (AUC = 0.92) than those with a midpoint of year 2001 or later (AUC = 0.83), although SROC curve shapes differed for earlier and later studies (P = .01). Examination of the curves indicated that earlier studies had consistently high sensitivity across the range of specificity values, whereas a trade-off between sensitivity and specificity at different thresholds was evident in later studies. With the evolution of MRI technology over time, it may appear counterintuitive that relatively lower accuracy was observed in more recent studies; however, a meta-analysis of preoperative MRI (71) also suggested similar findings. No clear differences in study quality between timeframes were observed to account for the above finding; however, it is possible that earlier studies may have involved radiologists with MRI expertise and that later studies involved readers with less MRI-dedicated expertise, reflecting broader adoption of MRI in breast imaging practice. It may also be possible that readers in more recent studies adjusted the implicit threshold used to define MRI positivity/negativity in response to the relatively lower specificity reported in many earlier studies.
In our subgroup analysis of studies that reported contrast enhancement thresholds applied to declare a positive or negative test, there was no statistically significant difference between thresholds for summary estimates of MRI sensitivity (ie, correct detection of residual malignancy) (0.83 vs 0.87; P = .45). However, MRI specificity (ie, correct identification of pCR) was statistically significantly greater when contrast enhancement equal to or less than normal breast tissue was considered negative for residual tumor compared with a complete absence of contrast uptake (0.83 vs 0.54; P = .02), which reflects the likelihood that enhancement caused by inflammatory or reactive changes post-NAC may be considered false positive for residual malignancy using the latter threshold. These findings raise concerns about MRI potentially underestimating the effect of NAC in achieving pCR where a stringent threshold is applied for defining the absence of residual malignancy; however, when pCR is identified by contrast enhancement equal to or less than normal breast tissue, the relatively higher specificity of MRI may allow better planning of breast conserving surgery. Standardization of MRI interpretation criteria/thresholds in this clinical setting is required.
Our analysis showed that the accuracy of MRI was statistically significantly higher than that of mammography (P = .02). There was only weak evidence suggesting that MRI also had greater accuracy than clinical examination (P = .10). Differences in summary accuracy estimates for MRI and ultrasound were not statistically significant (P = .15). These subgroup analyses were based on fewer studies because they were limited to studies that directly compared tests and, therefore, have relatively reduced power to detect differences in test accuracy. This may account for the lack of statistical differences between MRI and ultrasound accuracy in subgroup analysis; however, the findings may also represent true similarity in accuracy for MRI and ultrasound. We were unable to compare the accuracy of MRI with a combination of ultrasound and clinical examination because of a lack of studies that presented these data. The high relative cost of MRI, combined with potential advantages of clinical examination and ultrasound in terms of accessibility, suggest that a combination of the latter may be a reasonable alternative testing strategy to MRI in preoperative assessment after NAC. We recommend that future research aim to compare the combined accuracy of ultrasound and clinical examination with that of MRI in the NAC setting.
This study has some limitations. The reporting of information related to methodological quality was highly variable between studies and individual QUADAS items (see Supplementary Appendix F, available online), and some studies did not adequately describe MRI technical details (see Supplementary Appendix E, available online). Investigators should be encouraged to fully describe study methodology, MRI technology, and technique to allow the risk of bias and the generalizability of study findings to be assessed. Furthermore, relatively recent improvements in MRI technology that may be expected to potentially improve accuracy (eg, multichannel coils; ≥3-T magnets; contrast materials with high relaxivity; additional sequences allowing for diffusion weighted imaging) were underrepresented in studies included in this analysis. The effect of these developments on the accuracy of MRI should be the subject of further study.
In summary, our meta-analysis has shown good overall accuracy for MRI, although accuracy estimates varied with the definition of pCR, which highlights the importance of standardizing pCR definitions. Subgroup analysis also suggests that MRI may be more likely to be false positive for residual malignancy (thereby falsely underestimating the effect of NAC in achieving pCR) in studies that defined absence of residual malignancy on MRI as contrast enhancement less than or equal to that of normal breast tissue, rather than an absence of enhancement. In comparative studies, MRI was more accurate than mammography, but no differences in accuracy were observed between MRI and other less technically complex and costly tests (ultrasound, clinical examination). However, relatively few studies reported direct comparisons between MRI and other tests, and the comparative accuracy of MRI and combined ultrasound and clinical examination warrants further investigation in well-designed clinical trials.
